carbapenems has been researched along with amoxicillin in 16 studies
Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (amoxicillin) | Trials (amoxicillin) | Recent Studies (post-2010) (amoxicillin) |
---|---|---|---|---|---|
7,355 | 147 | 5,277 | 10,915 | 2,661 | 3,467 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (25.00) | 18.2507 |
2000's | 3 (18.75) | 29.6817 |
2010's | 3 (18.75) | 24.3611 |
2020's | 6 (37.50) | 2.80 |
Authors | Studies |
---|---|
Allen, S; Barry, A; Fuchs, P; McLaughlin, J; Pfaller, M; Sewell, D | 1 |
Appelbaum, PC; Jacobs, MR; Spangler, SK | 1 |
Verbist, L; Verhaegen, J | 1 |
Matsuda, K; Matsumoto, S; Matsumoto, Y; Sasaki, H; Takasugi, H; Yoshida, Y | 1 |
Appelbaum, PC; Davies, TA; Jacobs, MR; Pankuch, GA | 1 |
Billal, DS; Fujihara, K; Fukushima, T; Hotomi, M; Itahashi, K; Nagura, J; Shimada, J; Suzumoto, M; Yamanaka, N; Yamauchi, K | 1 |
Aguilar, L; Biek, D; Fenoll, A; Giménez, MJ; Granizo, JJ; Robledo, O; Tarragó, D | 1 |
Chiba, N; Morozumi, M; Ubukata, K | 1 |
Bauernfeind, A; Schneider, I | 1 |
Feng, J; Jia, R; Ju, Y; Li, J; Tang, N; Tian, J; Zhang, G | 1 |
Deligios, M; Fiamma, M; Paglietti, B; Rubino, S; Sacarlal, J; Santona, A; Simbine, SE; Sumbana, JJ; Taviani, E; Zimba, T | 1 |
Alfandari, S; Bajolet, O; Blanchard, H; Colomb-Cotinat, M; Daniau, C; Dumartin, C; Lecuru, M; Simon, L | 1 |
Dartois, V; Dick, T; Negatu, DA; Zimmerman, MD | 1 |
Gehlot, P; P, H | 1 |
Dalğıç, D; Kandemir, T; Nağıyev, T; Üçkayabaşı, A | 1 |
Ciszek, M; Hryniewiecka, E; Jasińska, K; Pączek, L; Wilkowski, P | 1 |
16 other study(ies) available for carbapenems and amoxicillin
Article | Year |
---|---|
Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Carbapenems; Cefaclor; Cefixime; Cefotaxime; Clavulanic Acids; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; United States | 1995 |
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cef
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Carbapenems; Cefaclor; Cefdinir; Cefixime; Cefotaxime; Cefpodoxime; Ceftizoxime; Cefuroxime; Cephalosporins; Clavulanic Acids; Microbial Sensitivity Tests; Penicillin G; Penicillin Resistance | 1994 |
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefaclor; Cefadroxil; Cefatrizine; Cefepime; Cefixime; Cefotaxime; Cefpirome; Cefpodoxime; Ceftazidime; Ceftibuten; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cephradine; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pneumococcal Infections; Serotyping; Species Specificity; Streptococcus pneumoniae | 1998 |
Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Clarithromycin; Disease Models, Animal; Helicobacter pylori; Lactams; Mice; Molecular Structure | 1999 |
Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.
Topics: Amoxicillin; Carbapenems; Humans; Microbial Sensitivity Tests; Penicillins; Streptococcus pneumoniae; Time Factors | 2002 |
Efficacy of a novel oral carbapenem, tebipenem pivoxil (TBM-PI), against experimental otitis media caused by penicillin resistant Streptococcus pneumoniae in chinchilla.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Carbapenems; Chinchilla; Male; Models, Animal; Otitis Media; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2007 |
In vitro activity of ME1036 versus other beta-lactams against penicillin-resistant Streptococcus pneumoniae serotypes exhibiting higher amoxicillin than penicillin MIC.
Topics: Amoxicillin; Anti-Bacterial Agents; Carbapenems; Humans; Microbial Sensitivity Tests; Penicillins; Pneumococcal Infections; Spain; Streptococcus pneumoniae | 2008 |
[Morphological changes in penicillin-resistant Streptococcus pneumoniae and beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae after exposure to oral antibacterial agents].
Topics: Amoxicillin; Ampicillin Resistance; Anti-Bacterial Agents; Bacteriolysis; beta-Lactamases; Carbapenems; Cephalosporins; Child; Dose-Response Relationship, Drug; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Microscopy, Phase-Contrast; Naphthyridines; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae; Time Factors | 2012 |
Intrinsic carbapenem-hydrolyzing oxacillinases from members of the genus Pandoraea.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Imipenem; Piperacillin | 2015 |
Five novel carbapenem-hydrolysing OXA-type β-lactamase groups are intrinsic in Acinetobacter spp.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Computational Biology; Drug Resistance, Bacterial; Escherichia coli; Gene Knockout Techniques; Hydrolysis; Imipenem; Microbial Sensitivity Tests; Phylogeny | 2018 |
High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in Maputo Central Hospital, Mozambique.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Extraintestinal Pathogenic Escherichia coli; Gentamicins; Hospitals; Humans; Iron; Mozambique; Piperacillin; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Evolution of antibiotic treatments for healthcare-associated infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in France.
Topics: Aminoglycosides; Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Cross Infection; Delivery of Health Care; Enterobacteriaceae; Enterobacteriaceae Infections; France; Humans; Nitrofurantoin; Ofloxacin; Penicillins; Urinary Tract Infections | 2022 |
Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cefuroxime; Humans; Lactams; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium abscessus | 2022 |
Computational and data mining studies to understand the distribution and dynamics of Temoneria (TEM) β-lactamase and their interaction with β-lactam and β-lactamase inhibitors.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Data Mining; Molecular Docking Simulation; Monobactams; Penicillins; Tazobactam | 2022 |
[Relationship of Hypervirulent Capsular Genotypes of Klebsiella pneumoniae with Antibiotic Susceptibility and Beta-Lactamase Genes].
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clavulanic Acid; Colistin; Drug Resistance, Bacterial; Genotype; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin; Tazobactam | 2023 |
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections Due to Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clavulanic Acid; Drug Resistance, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Urinary Tract Infections | 2023 |